Table 5 Cox proportional hazards regression analysis of PFS and OS in KRAS-mutated patients.

From: Correlation analysis between RAS gene mutations and pathological morphological features in colorectal cancer

Characteristic

OS

PFS

Univariate analysis HR (95% CI)

P-value

Multivariateanalysis HR (95% Cl)

P-value

Univariate analysis HR (95% CI)

P-value

Multivariateanalysis HR (95% Cl)

P-value

G12C

Wild type

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Mutant

1.35 (0.80–2.30)

0.261

1.25 (0.72–2.18)

0.430

1.20 (0.75–1.92)

0.447

1.15 (0.70–1.89)

0.580

G12D

Wild type

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Mutant

0.90 (0.58–1.40)

0.642

0.85 (0.53–1.37)

0.510

0.95 (0.65–1.40)

0.798

0.90 (0.60–1.35)

0.620

G12V

Wild type

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Mutant

1.15 (0.68–1.95)

0.595

1.10 (0.63–1.92)

0.730

1.10 (0.70–1.73)

0.672

1.05 (0.65–1.70)

0.840

G13D

Wild type

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Mutant

0.80 (0.48–1.33)

0.390

0.75 (0.44–1.29)

0.300

0.85 (0.55–1.30)

0.450

0.80 (0.50–1.28)

0.350

TP53

Wild type

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Mutant

1.25 (0.82–1.90)

0.299

1.20 (0.78–1.85)

0.400

1.15 (0.80–1.65)

0.450

1.10 (0.75–1.60)

0.620

APC

Wild type

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Mutant

0.85 (0.55–1.30)

0.450

0.80 (0.51–1.26)

0.340

0.90 (0.62–1.30)

0.575

0.85 (0.58–1.25)

0.420

PIK3CA

Wild type

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Mutant

1.50 (0.95–2.35)

0.080

1.35 (0.85–2.15)

0.200

1.40 (0.95–2.05)

0.008

1.30 (0.88–1.93)

0.190

Age

<60 years

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

≥ 60 years

1.10 (0.80–1.50)

0.570

1.05 (0.75–1.47)

0.780

1.20 (0.85–1.70)

0.300

1.15 (0.80–1.65)

0.450

Gender

Male

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Female

0.95 (0.70–1.30)

0.75

0.90 (0.65–1.25)

0.530

0.90 (0.63–1.28)

0.550

0.85 (0.59–1.23)

0.390

Tumor location

Left-sided colon

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Right-sided colon

1.40 (0.85–2.30)

0.180

1.30 (0.78–2.17)

0.310

1.30 (0.85-2.00)

0.220

1.25 (0.80–1.95)

0.340

 

Rectum

1.05 (0.63–1.75)

0.850

1.00 (0.58–1.72)

0.990

1.10 (0.70–1.73)

0.670

1.05 (0.65–1.70)

0.850

TNM stage

Stage I

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Stage II–III

2.30 (1.20–4.40)

0.012*

2.10 (1.08–4.08)

0.029*

2.00 (1.10–3.65)

0.024*

1.85 (1.00-3.42)

0.050*

 

Stage IV

4.00 (2.15–7.45)

<0.001**

3.60 (1.90–6.82)

<0.001**

3.50 (2.00-6.10)

<0.001**

3.20 (1.80–5.70)

<0.001**

Tumor differentiation

Well

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

Moderate

1.40 (0.80–2.45)

0.240

1.30 (0.73–2.32)

0.370

1.30 (0.80–2.10)

0.280

1.20 (0.75–1.93)

0.450

 

Poor

2.00 (1.15–3.50)

0.014*

1.85 (1.05–3.26)

0.034*

1.80 (1.10–2.95)

0.019*

1.65 (1.00-2.72)

0.049*

MSI/MMR status

MSS/pMMR

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

MSI-H/dMMR

0.55 (0.25–1.20)

0.130

0.60 (0.27–1.33)

0.210

0.60 (0.30–1.20)

0.150

0.65 (0.32–1.32)

0.230

Primary tumor resection

Yes

1 (reference)

-

1 (reference)

-

1 (reference)

-

1 (reference)

-

 

No

3.20 (2.05-5.00)

<0.001**

2.90 (1.82–4.62)

<0.001**

2.80 (1.90–4.10)

<0.001**

2.60 (1.75–3.86)

<0.001**

Back to article page